Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia - Wikidata - wikimedia - TriplyDB

Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia

Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia

http://www.wikidata.org/entity/Q28469040

about

Disease biomarkers in cerebrospinal fluid of patients with first-onset psychosis Pyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in cancer cells Advantages and Pitfalls of Mass Spectrometry Based Metabolome Profiling in Systems Biology Omics-Based Biomarkers: Application of Metabolomics in Neuropsychiatric Disorders Metabolomics of oxidative stress in recent studies of endogenous and exogenously administered intermediate metabolites Better understanding of mechanisms of schizophrenia and bipolar disorder: from human gene expression profiles to mouse models Obesity and psychotic disorders: uncovering common mechanisms through metabolomics Cannabidiol as a Potential New Type of an Antipsychotic. A Critical Review of the Evidence Independent protein-profiling studies show a decrease in apolipoprotein A1 levels in schizophrenia CSF, brain and peripheral tissues Increased alpha-defensins as a blood marker for schizophrenia susceptibility CSF metabolic and proteomic profiles in patients prodromal for psychosis.Molecular substrates of schizophrenia: homeostatic signaling to connectivity Brain region mapping using global metabolomics.Metabolic Profiling and Phenotyping of Central Nervous System Diseases: Metabolites Bring Insights into Brain Dysfunctions.Piecewise multivariate modelling of sequential metabolic profiling data Metabolic profiling of patients with schizophrenia The estrogen hypothesis of schizophrenia implicates glucose metabolism: association study in three independent samples 'Systems toxicology' approach identifies coordinated metabolic responses to copper in a terrestrial non-model invertebrate, the earthworm Lumbricus rubellus Metabolic profiling of an Echinostoma caproni infection in the mouse for biomarker discovery.The cerebral microvasculature in schizophrenia: a laser capture microdissection study.Gene expression in the prefrontal cortex during adolescence: implications for the onset of schizophrenia Clinical bioinformatics for complex disorders: a schizophrenia case study.Metabolomic profiling in LRRK2-related Parkinson's disease Molecular characterization and quantification using state of the art solid-state adiabatic TOBSY NMR in burn trauma.Linking mechanistic and behavioral responses to sublethal esfenvalerate exposure in the endangered delta smelt; Hypomesus transpacificus (Fam. Osmeridae)A snapshot of plasma metabolites in first-episode schizophrenia: a capillary electrophoresis time-of-flight mass spectrometry study Systems-level metabolic flux profiling identifies fatty acid synthesis as a target for antiviral therapy.Metabolomics in drug target discovery.S100B Serum Levels in Schizophrenia Are Presumably Related to Visceral Obesity and Insulin Resistance Inflammatory molecular signature associated with infectious agents in psychosis.Evidence for disturbed insulin and growth hormone signaling as potential risk factors in the development of schizophrenia Metabolic profiling and the metabolome-wide association study: significance level for biomarker identification.Navigating the human metabolome for biomarker identification and design of pharmaceutical molecules.Selection of reference gene expression in a schizophrenia brain cohort.Metabolic abnormalities in fronto-striatal-thalamic white matter tracts in schizophrenia.IgG dynamics of dietary antigens point to cerebrospinal fluid barrier or flow dysfunction in first-episode schizophrenia.Metabolome in schizophrenia and other psychotic disorders: a general population-based study.Mass spectrum analysis of serum biomarker proteins from patients with schizophrenia.The promise of biological markers for treatment response in first-episode psychosis: a systematic review.Human metabolic profiles are stably controlled by genetic and environmental variation.

P2860

Q21144689-BEA827C5-C408-43D2-A78F-78383C0693C3 Q24320179-02BA9FE1-0099-4097-8237-C782F4BCBA3F Q26748877-7CF348DF-4693-46FC-9B27-D38FA7CB4739 Q26784904-318AB47E-FCCD-4982-AD89-C49DF86099CD Q26824720-389B52F3-14BD-4E7C-A07B-20764F786455 Q26866254-952D5BE4-06F9-42DD-A798-C6C6E9A2BCCF Q27011617-EBA131AA-7740-4DCA-BEF8-F8FB9447467D Q28075499-3B092DA5-5404-4518-80BD-CAF1347ECDE0 Q28253419-1CAA16DD-C002-4821-9BAF-702F22CADB5B Q28273093-5177E4D3-1E9C-4201-BB69-916B82EF3A1C Q28469277-42DF1C0E-09BC-4BDD-8456-A55137C7A68E Q30383611-396DF7A9-119C-4AE9-8B6B-0B7C49C20603 Q30873368-BA4185DE-BA86-4297-8DB3-4C7B28102EC0 Q30885784-4B8BD754-33E7-4D7C-BA0A-F0CDC4EFC497 Q31147103-E7848AC2-3775-4686-8C31-FA122C32C5B8 Q33255317-51FDDDB7-5709-47C1-93A5-AA0B79FFB41D Q33332023-1E9C4987-1F9D-4A09-9C0B-39B0071E7C17 Q33340135-A7495EDA-34BA-466E-95A1-E236A0B1E0DD Q33348638-08245F2E-8784-49F7-BF07-D26A699ADA88 Q33393640-7D2BC756-8404-4E98-9A56-92DDF67B9413 Q33448981-02357EFA-73BB-4A69-89B2-768230EC6136 Q33510480-4447CBD4-6234-4821-8BD5-8CA10DE286C9 Q33511761-2883DBF8-1C1B-43C1-8FC3-60B72EEA9A0C Q33514649-471E23C4-6EC4-4257-85B3-59D310267A11 Q33518044-ED872463-76BC-49F1-A1B5-5AC8B38711DD Q33575018-9EB014B1-8B1D-4ED2-A301-6F43875F3A88 Q33675261-BBED35D4-1961-449D-8F3A-A321E1E0BBDB Q33854683-8FA69171-783E-422F-9657-D5F4CB362F04 Q33984573-D80E10A2-332D-43D3-98C2-213345C72DE7 Q34048637-812323C8-580B-4858-AAFE-387ABC6E3660 Q34113374-B07A76B5-8EA2-4E7D-9AD9-90B5D8A0E466 Q34135639-0A893D37-BD10-4BC6-945C-2B256DCB627F Q34170091-6B4880CF-5D4F-42CE-99EC-D0AB3E834EF5 Q34176902-0F4138D4-2AF7-4063-993A-414037E6D1D8 Q34213211-E273F949-2E6A-42C2-AE6C-93E92070D717 Q34764938-DD8C8E78-9DA1-4D3B-8B2E-4BB5573F974D Q34971495-9B2A2D54-7558-4B86-A795-187C17E1E841 Q35047339-2E01EA3A-5A54-4AAA-A006-BC700E8EB6CE Q35369988-D22B26F8-5E56-4677-A715-05212711C884 Q35458562-3E7F4B1E-94F9-4125-A526-B8D94C700661

P2860

Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia

http://www.wikidata.org/entity/Q28469040

description

2006 nî lūn-bûn

@nan

2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Metabolic profiling of CSF: ev ...... n and outcome in schizophrenia

@ast

Metabolic profiling of CSF: ev ...... n and outcome in schizophrenia

@en

Metabolic profiling of CSF: ev ...... n and outcome in schizophrenia

@nl

type

label

Metabolic profiling of CSF: ev ...... n and outcome in schizophrenia

@ast

Metabolic profiling of CSF: ev ...... n and outcome in schizophrenia

@en

Metabolic profiling of CSF: ev ...... n and outcome in schizophrenia

@nl

prefLabel

Metabolic profiling of CSF: ev ...... n and outcome in schizophrenia

@ast

Metabolic profiling of CSF: ev ...... n and outcome in schizophrenia

@en

Metabolic profiling of CSF: ev ...... n and outcome in schizophrenia

@nl

P1433

Q28469040-A1577289-5E6B-4277-8384-8AF3EEBAAA04

P1476

Q28469040-1BC14FF7-EA26-4B43-9B58-50FFCFC0A99A

P2093

Q28469040-58596012-2376-4EFC-BA47-FA487469FFC3

Q28469040-8135E6CF-06E7-45A9-9DA2-C35D69187C69

Q28469040-8C8BFE0F-EEB1-4697-BBF3-662F510BCE46

Q28469040-B4D4C204-B012-47AB-A182-106C737EAFDA

Q28469040-B8170FAC-8645-4904-A220-CCECF64C06A3

Q28469040-EAEE25C8-388F-4EAB-B803-BB8A7ECAD38C

Q28469040-F2940157-6BF6-4D32-8A69-99C1EF93422B

P2860

Q28469040-09580BB5-9606-4D38-9B56-4225F0B3AF60

Q28469040-131FEDF6-EFB2-4696-9B2D-1400C857107C

Q28469040-1393B00E-6A6F-4374-9860-43708D81F29F

Q28469040-149CBA45-000A-4300-B33E-7CDB71ACC698

Q28469040-15093C44-3B17-4997-A80E-4E4B8E8BB185

Q28469040-1C76604F-E96D-42D3-89CE-DD0E319FAF30

Q28469040-1DA6EA61-2782-4EBA-87FC-AFF954B8A4E8

Q28469040-20D8B59A-D067-4E02-A84F-3856E3CC26F9

Q28469040-2977C261-ECED-4400-A33D-0BD7AC0080B6

Q28469040-2D4F4DCD-C6C0-4633-924A-56291036A880

P304

Q28469040-5B96665E-A0FA-4E15-8FBA-51305D1161B7

P31

Q28469040-9C737605-5FD9-4716-9AF1-D76549C359F0

P3181

Q28469040-53CA17DC-93C4-4325-A9FA-0E51E61858CA

P356

Q28469040-06D49636-095B-4E9E-ACE0-C4B5009B4F20

P407

Q28469040-C6A754DB-F9CE-43E5-88A3-59DAA80BC41B

P433

Q28469040-FA58D0B7-6FD2-4908-BA5F-713439DAD8C1

P478

Q28469040-7B74FBD3-235F-4880-8755-FF13C1F64C7E

P50

Q28469040-1CE19706-4544-45C5-AA80-0C9AA14704DB

Q28469040-423A9C5B-9DE3-46EE-9C74-2CCEF2FF481A

Q28469040-662407C3-0EF0-4DE0-83F3-4169F825BA47

Q28469040-B72173F1-92EE-4985-BB0B-04FAB262E0A1

P577

Q28469040-A3119924-81FD-4734-BD10-6284B9B6D389

P5875

Q28469040-1F8CF7F8-66C7-41A1-846B-5B97BE21CF43

P698

Q28469040-9B81729B-8E93-4F82-8F16-673065129E0C

P921

Q28469040-AAB8D5EE-A75F-4B9E-8C46-28B843AEA974

P932

Q28469040-2AD39066-7914-4DDF-8CF9-333DB0997719

P3181

P356

JOURNAL.PMED.0030327

P1433

P1476

Metabolic profiling of CSF: ev ...... n and outcome in schizophrenia

@en

P2093

Brit M Nolden

http://www.w3.org/2001/XMLSchema#string

Christoph W Gerth

http://www.w3.org/2001/XMLSchema#string

Daniela Schreiber

http://www.w3.org/2001/XMLSchema#string

F Markus Leweke

http://www.w3.org/2001/XMLSchema#string

Jeffrey T-J Huang

http://www.w3.org/2001/XMLSchema#string

Sonja Gross

http://www.w3.org/2001/XMLSchema#string

Tsz M Tsang

http://www.w3.org/2001/XMLSchema#string

P2860

Elevated glutamine/glutamate ratio in cerebrospinal fluid of first episode and drug naive schizophrenic patients

Intraneuronal N-acetylaspartate supplies acetyl groups for myelin lipid synthesis: evidence for myelin-associated aspartoacylase

Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis

Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress

'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data

Application of chemometrics to 1H NMR spectroscopic data to investigate a relationship between human serum metabolic profiles and hypertension.

Measurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and meta-analysis.

Defective N-acetylaspartate catabolism reduces brain acetate levels and myelin lipid synthesis in Canavan's disease.

Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia.

Metabonomics: a platform for studying drug toxicity and gene function.

P304

e327

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1391660

http://www.w3.org/2001/XMLSchema#string

P356

10.1371/JOURNAL.PMED.0030327

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

Jeremy K. Nicholson

P577

2006-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6854466

http://www.w3.org/2001/XMLSchema#string

P698

16933966

http://www.w3.org/2001/XMLSchema#string

P921

P932

1551919

http://www.w3.org/2001/XMLSchema#string